Sales & Marketing How data is critical to commercialising drugs for rare disea... Orphan drugs are designed to treat rare diseases, but “rare” is a relative term.
R&D Pharma gets ruthless as job losses mount across industry The industry is showing its teeth, as companies have started slashing positions.
News Appeal finds NICE must reconsider Alzheimer's drugs Lilly and Eisai's bid to secure NHS coverage of their Alzheimer's therapies has entered a new phase, after an appeal of last year's rejection by NICE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
